Enliven Q3 Loss Widens to $27.7 Million Ahead of First Pivotal Trial
Enliven Therapeutics reported third-quarter 2026 results on November 5, 2026, posting a net loss of $27.7 million for the quarter ended September 30, compared with $20.1 million a year earlier, as the clinical-stage company prepared for its first pivotal trial. Research and development expenses rose to $28.0 million from $18.2 million in the third quarter of 2025, while general and administrative expenses increased to $8.0 million from $6.9 million. Total operating expenses reached $36.0…